L19IL2/TNF in Patients With Basal Cell Carcinoma
A phase 2 trial of L19IL2/L19TNF in basal cell carcinoma, run by Philogen S.p.A., now recruiting.
Overview
L19IL2/TNF in Patients With Basal Cell Carcinoma is a phase 2 interventional study registered as NCT07227870 by Philogen S.p.A., with 92 participants planned, started 2026-09 and due to reach its primary completion in 2031-02. Interventions recorded: L19IL2/L19TNF.
Similar pages
not linked directly; found by shared links- TrialL19IL2 or L19TNF or L19IL2/TNF in Patients With Basal Cell Carcinoma (BCC)
Shares Philogen S.p.A., Basal cell carcinoma and the tag pipeline.
- TrialNeoadjuvant L19IL2/L19TNF- Pivotal Study
Shares Philogen S.p.A. and the tag pipeline.
- TrialEfficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
Shares Philogen S.p.A. and the tag pipeline.
- TrialA Study With L19TNF in Combination With Lomustine in Patients With Glioblastoma at Progression or Recurrence
Shares Philogen S.p.A. and the tag pipeline.
- TrialEfficacy and Safety of Patidegib Gel 2% for Preventing Basal Cell Carcinomas on the Face of Adults With Gorlin Syndrome
Shares Basal cell carcinoma and the tag pipeline.
- TrialClinical Trial to Evaluate BO-112 in Patients With Basal Cell Carcinoma (BCC)
Shares Basal cell carcinoma and the tag pipeline.
- TrialSafety and Efficacy of L19TNF Plus Temozolomide Chemoradiotherapy in Patients With Newly Diagnosed Glioblastoma
Shares Philogen S.p.A. and the tag pipeline.
- TrialPlacebo Microneedles in Healthy Volunteers (Part I) and Efficacy/Safety of Doxorubicin Microneedles in Basal Cell Cancer Subjects (Part II)
Shares Basal cell carcinoma and the tag pipeline.